These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16620363)
1. Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. O'Callaghan DS; Gaine SP Int J Clin Pract; 2006 Apr; 60(4):475-81. PubMed ID: 16620363 [TBL] [Abstract][Full Text] [Related]
2. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Horn EM; Widlitz AC; Barst RJ Expert Opin Investig Drugs; 2004 Nov; 13(11):1483-92. PubMed ID: 15500395 [TBL] [Abstract][Full Text] [Related]
3. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Waxman AB Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185 [TBL] [Abstract][Full Text] [Related]
12. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade. Langleben D; Cacoub P Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350 [TBL] [Abstract][Full Text] [Related]